Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Enveric Biosciences

Enveric Biosciences Advances Non-Hallucinogenic DMT Analog Drug With Promising Preclinical Results

Psychedelics biotech company Enveric Biosciences (NASDAQ:ENVB) completed preclinical pharmacokinetic (PK) studies for its leading drug candidate EB-003 aimed at treating depression and anxiety without causing hallucinations. EB-003 is a neuroplastic and non-hallucinogenic N, N-Dimethyltryptamine (DMT) analog drug candidate., such as ataxia or hyperthermia.

World Class Leaders In Psychedelics Form Benzinga's Psychedelic Advisory Council—Get To Know Them

World Class Leaders In Psychedelics Form Benzinga's Psychedelic Advisory Council—Get To Know Them

The Benzinga Psychedelics Advisory Council was introduced in March of 2022 with the sustained goal of better informing investors and general audience about the psychedelics financial and business landscape.

12 Health Care Stocks Moving In Friday's Intraday Session

12 Health Care Stocks Moving In Friday's Intraday Session

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

12 Health Care Stocks Moving In Thursday's Intraday Session

12 Health Care Stocks Moving In Thursday's After-Market Session

Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2022

EXCLUSIVE: NASDAQ-Listed Enveric To Split Into Two Companies, One For Cannabinoids, One For Psychedelics

Enveric Biosciences (NASDAQ: ENVB), a biotech company working with cannabinoids and psychedelics, announced it will spin off its cannabinoid pipeline into a separate public company that will also be listed on the NASDAQ, and will be called Acanna Therapeutics Inc.

inkl

Read news from The Economist, FT, and more,
with one subscription

12 Health Care Stocks Moving In Tuesday's After-Market Session

12 Health Care Stocks Moving In Tuesday's After-Market Session

Five Companies Developing Second Generation Psychedelics For Mental Health

Five Companies Developing Second Generation Psychedelics For Mental Health

Along with the psychedelic renaissance came a new type of drug: second generation psychedelics. Developed from classic psychedelics molecules, these upgraded compounds could offer improved therapeutic profiles with reduced side effects. For some companies in the psychedelics space, second generation psychedelics could be the key to success in an increasingly…

Psilocybin For Cancer Related Distress: Enveric To Launch Clinical Trial In Partnership With University of Calgary

Psilocybin For Cancer Related Distress: Enveric To Launch Clinical Trial In Partnership With University of Calgary

Enveric Biosciences (NASDAQ: ENVB) a neuroscience company developing psychedelics and cannabinoids into mental health medicines, announced a collaboration with the University of Calgary’s Hotchkiss Brain Institute.

Enveric Biosciences Closes $10 Million Public Offering

Enveric Biosciences Closes $10 Million Public Offering

Psychedelics-based company Enveric Biosciences (NASDAQ: ENVB) has closed its previously announced underwritten public offering of 20 million shares of its common stock and warrants to purchase up to 20 million shares of its common stock for gross proceeds of approximately $10 million, befor

Cannabis For Arthritis: Enveric Biosciences Files Patent On CBD Medication For Osteoarthritis

Cannabis For Arthritis: Enveric Biosciences Files Patent On CBD Medication For Osteoarthritis

Psychedelics and cannabinoid neuroscience company Enveric Biosciences (NASDAQ: ENVB) announced the development of two new molecular conjugates for osteoarthritis and other pain indications, which mix CBD with Celecoxib, a generic drug commonly prescribed for osteoarthritis.

1

Organisations

Vertex Pharmaceuticals

Field Trip Health

Blueprint Medicines

GoodRx Holdings

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

398,365 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play